Biologics for the Treatment of Rheumatoid Arthritis (eBook)
XIII, 132 Seiten
Springer International Publishing (Verlag)
978-3-319-13108-5 (ISBN)
Professor Ronald F van Vollenhoven is Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute, and of the Clinical Trials Unit Rheumatology at the Karolinska University Hospital. He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by a residency (specialty training) in internal medicine at the State University of New York at Stony Brook, and a fellowship in rheumatology at Stanford University in Palo Alto following which he received American Board of Internal Medicine certification in both internal medicine and rheumatology. From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 Professor van Vollenhoven moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; and in 2010, he was appointed in his current position as Professor and Unit Chief at the Karolinska Institute.
Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biologic and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he has established the Stockholm registry for biological therapies (the STURE database) for this purpose, which has supported research projects relating to clinical efficacy, pharmacology, outcomes, and pharmacoeconomics. He has been principal investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT trial. He has published over 240 original papers, book chapters and reviews, and is Editor of the textbook Targeted Treatment of the Rheumatic Diseases and associate-editor of Dubois' Lupus Erythematosus. In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatology societies. He is the Editor-in-Chief of Lupus Science & Medicine, Chair of the EULAR Standing Committee on Clinical Affairs, member of many editorial boards, past-chair of the Swedish Rheumatology Society Professors' Council, co-founder of the IRBIS registry for biologics in systemic lupus erythematosus (SLE), the CERERRA registries collaboration, and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE initiative. Professor van Vollenhoven lives just north of Stockholm with his wife and children aged 20 and 16. Outside his professional life he is an avid classical pianist.
Professor Ronald F van Vollenhoven is Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute, and of the Clinical Trials Unit Rheumatology at the Karolinska University Hospital. He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by a residency (specialty training) in internal medicine at the State University of New York at Stony Brook, and a fellowship in rheumatology at Stanford University in Palo Alto following which he received American Board of Internal Medicine certification in both internal medicine and rheumatology. From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 Professor van Vollenhoven moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; and in 2010, he was appointed in his current position as Professor and Unit Chief at the Karolinska Institute.Professor van Vollenhoven’s research interests focus around the development and systematic evaluation of biologic and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he has established the Stockholm registry for biological therapies (the STURE database) for this purpose, which has supported research projects relating to clinical efficacy, pharmacology, outcomes, and pharmacoeconomics. He has been principal investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT trial. He has published over 240 original papers, book chapters and reviews, and is Editor of the textbook Targeted Treatment of the Rheumatic Diseases and associate-editor of Dubois’ Lupus Erythematosus. In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatology societies. He is the Editor-in-Chief of Lupus Science & Medicine, Chair of the EULAR Standing Committee on Clinical Affairs, member of many editorial boards, past-chair of the Swedish Rheumatology Society Professors’ Council, co-founder of the IRBIS registry for biologics in systemic lupus erythematosus (SLE), the CERERRA registries collaboration, and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE initiative. Professor van Vollenhoven lives just north of Stockholm with his wife and children aged 20 and 16. Outside his professional life he is an avid classical pianist.
Disease overview.- General treatment aspects.- Overview of biologic therapies.- Cytokine inhibitors.- B-cell directed therapy.- T-cell directed therapy.- Novel biologics and small molecules with biologic-like effects.- Strategies for the optimal use of biologic agents in rheumatoid arthritis.- Considerations for special patient populations.- Conclusions and future outlook
Erscheint lt. Verlag | 22.12.2015 |
---|---|
Zusatzinfo | XIII, 132 p. 40 illus., 3 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete |
Schlagworte | Biologics • immunology • Inflammatory rheumatic disease • Rheumatoid Arthritis • rheumatology |
ISBN-10 | 3-319-13108-7 / 3319131087 |
ISBN-13 | 978-3-319-13108-5 / 9783319131085 |
Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
Haben Sie eine Frage zum Produkt? |
Größe: 4,0 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich